THISTLE - The HIV-HCV Silibinin Trial
NCT01816490
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
HIV
Hepatitis C
Interventions
DRUG:
Intravenous Silibinin (iSIL)
Sponsor
University of Zurich